BAUSCH HEALTH COMPANIES WKN: A2JQ1X ISIN: CA0717341071 Kürzel: BHC Forum: Aktien Thema: Hauptdiskussion

Kaufe sie wirklich gerne für 15, da sie schon bald 100 Euro Wert sein dürften.

Jo da habe ich jetzt noch etwas nachgekauft

BHC:  Bausch Health sees Q3 revs above consensus; sees FY20 revs in line  (16.08) Co issues upside guidance for Q3 (Sep), sees Q3 (Sep) revs of more than $2.1 bln vs. $1.98 bln S&P Capital IQ Consensus. Co issues in-line guidance for FY20 (Dec), sees FY20 (Dec) revs of near midpoint of $7.8-8.0 bln vs. $7.86 bln S&P Capital IQ Consensus; sees FY20 EBTIDA near the midpoint of $3.15-3.30 bln

schon wieder 😂

Ah okay, danke@

Die Prognose wurde angehoben

Ähm, gibt's News oder was passiert hier?

Damit könnten sie Schulden bezahlen

Wir brauchen mal ein Aktienrückkaufprogramm. Diese sollten Sie selber halten und wieder verkaufen wenn der Kurs oben ist.

Gibt es mal was neues hier? Die dümpelt so vor sich hin, ob das noch mal was wird :/

Nein aus dem November 2019.

Schöner Artikel, aber nicht mehr ganz neu, oder?

http://www.intelligent-investieren.net/2019/11/bausch-health-shortseller-citron.html?m=1

Die News sind seit 2017 zu 80% Top. Joe Papa macht einen ausgezeichneten Job. Auch die news zur Übernahme von Kompetenzen ist super bin ehr der Ansicht bei diesen Kursen nochmal nachzulegen.

nützt alles nichts... die Aussichten bleiben schlecht.

Bausch Health to acquire option for Allegro assets 2020-09-21 08:05 ET - News Release Mr. Joseph Papa reports BAUSCH HEALTH TO ACQUIRE OPTION TO PURCHASE ALL OPHTHALMOLOGY ASSETS OF ALLEGRO OPHTHALMICS Bausch Health Companies Inc. has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate integrin functions for the treatment of ocular diseases, including global rights for risuteganib (Luminate) (1), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry age-related macular degeneration (AMD). It is estimated that as many as 16 million people in the United States have AMD2, and globally, the prevalence of AMD is expected to reach 196 million people worldwide this year and to increase to 288 million by 2040.3 Approximately 90 percent of people diagnosed with AMD have dry AMD, for which there are currently no treatments.4 "As part of the ongoing transformation of Bausch Health, we continue to seek strategic opportunities to build-up our pipeline in core businesses, including Bausch + Lomb, our global eye health business. The addition of the ophthalmic assets of Allegro would significantly enhance our comprehensive portfolio of products for AMD," said Joseph C. Papa, chairman and CEO of Bausch Health. "If approved, risuteganib may be the first treatment indicated to help reverse vision loss due to dry AMD and would address a significant unmet medical need affecting millions of people globally." "Allegro is excited to partner with Bausch Health, an established global player in ophthalmology that values the potential of risuteganib and our integrin-regulating platform as much as we do," said Vicken Karageozian, M.D., president and CEO, Allegro. "As we prepare for our Phase 3 clinical program, we look forward to working closely with Bausch Health on the united goal of one day being able to offer a treatment option to the millions of people who are currently losing their vision to dry AMD." Risuteganib is an investigational integrin-regulating therapy that is believed to reduce mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib may help reduce the cellular burden of oxidative stress and restore retinal homeostasis.5 Two concurrent Phase 3 studies evaluating the use of intravitreal risuteganib to treat intermediate dry AMD are expected to begin within the next 12 months. Other ophthalmology assets of Allegro include ALG-1007, a topical integrin regulator under investigation for the treatment of dry eye disease. It is currently in Phase 2 development outside the United States. The Option payment totaling $50 million would be made in two tranches, with the first payment of $10 million upon signing. Allegro intends to raise additional funding, following which, Bausch Health will make a second payment of $40 million, which is expected to be made in 2021. If Bausch Health then elects to exercise the Option, additional payments will be payable. About Bausch + Lomb